Title |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
|
---|---|
Published by |
John Wiley & Sons, Ltd, January 2012
|
DOI | 10.1002/14651858.cd008965.pub3 |
Pubmed ID | |
Authors |
Jefferson, Tom, Jones, Mark A, Doshi, Peter, Del Mar, Chris B, Heneghan, Carl J, Hama, Rokuro, Thompson, Matthew J |
Abstract |
Planning for outbreaks of influenza is a high priority public health issue for national governments. Neuraminidase inhibitors (NIs) are thought to help reduce the symptoms of influenza with several possible mechanisms proposed. NIs have been stockpiled with a view to their widespread use in the event of a pandemic. However, the evidence base for this class of agents remains a source of debate. In a previous review we have documented substantial risks of publication bias of trials of NIs for influenza (60% of patient data from phase III treatment trials of oseltamivir have never been published) and reporting bias in the published trials. Our confidence in the conclusions of previous versions of this review has been subsequently undermined. Since we have become aware of a large number of unpublished trials of NIs in the management of influenza, this review updates and merges existing reviews in this area. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 5 | 11% |
Japan | 4 | 9% |
Mexico | 3 | 7% |
Norway | 3 | 7% |
Germany | 2 | 4% |
United Kingdom | 2 | 4% |
Australia | 2 | 4% |
Netherlands | 1 | 2% |
Italy | 1 | 2% |
Other | 7 | 16% |
Unknown | 15 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 36 | 80% |
Scientists | 5 | 11% |
Practitioners (doctors, other healthcare professionals) | 4 | 9% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 99 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 2 | 2% |
Unknown | 97 | 98% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 1% |
Medicine and Dentistry | 1 | 1% |
Unknown | 97 | 98% |